BIRC5 and central nervous system cancer: SurVaxM (SVN53-67/M57-KLH) peptide vaccine to treat glioma contains the 53–67 amino-acid survivin sequence with a mutation in position 57 to enhance antigenicity conjugated to the protein Keyhole Limpet Hemocyanin [30].